Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $40.26, for a total transaction of $805,200.00. Following the completion of the transaction, the executive vice president directly owned 20,000 shares in the company, valued at $805,200. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Marshall Urist also recently made the following trade(s):

• On Friday, January 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $39.52, for a total transaction of $790,400.00.
• On Friday, January 9th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $40.78, for a total transaction of $815,600.00.
• On Friday, December 26th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $39.32, for a total value of $786,400.00.
• On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.38, for a total value of $767,600.00.
• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.32, for a total value of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total value of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total value of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The stock was sold at an average price of $39.93, for a total value of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.90, for a total transaction of $727,855.80.

Royalty Pharma Stock Performance

Shares of RPRX opened at $40.47 on Tuesday. The company has a 50-day moving average of $39.37 and a two-hundred day moving average of $37.61. The stock has a market cap of $23.36 billion, a price-to-earnings ratio of 30.66, a PEG ratio of 1.54 and a beta of 0.43. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.48 and a quick ratio of 3.48. Royalty Pharma PLC has a one year low of $29.66 and a one year high of $41.70.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, beating the consensus estimate of $1.11 by $0.06. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. The business had revenue of $609.29 million during the quarter, compared to the consensus estimate of $765.01 million. On average, equities research analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 20th will be given a $0.235 dividend. This represents a $0.94 annualized dividend and a dividend yield of 2.3%. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Friday, February 20th. Royalty Pharma’s payout ratio is 66.67%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Smartleaf Asset Management LLC boosted its holdings in Royalty Pharma by 868.1% in the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 790 shares in the last quarter. USA Financial Formulas acquired a new stake in shares of Royalty Pharma in the second quarter worth about $32,000. Private Trust Co. NA lifted its position in shares of Royalty Pharma by 52.9% in the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 288 shares during the last quarter. Financial Consulate Inc. bought a new stake in shares of Royalty Pharma during the 3rd quarter worth about $35,000. Finally, Larson Financial Group LLC increased its holdings in shares of Royalty Pharma by 31.9% during the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 306 shares during the last quarter. Institutional investors own 54.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on RPRX shares. TD Cowen reissued a “buy” rating on shares of Royalty Pharma in a research note on Thursday, December 11th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Royalty Pharma in a research report on Thursday. Leerink Partners set a $45.00 price target on shares of Royalty Pharma in a report on Thursday, December 11th. The Goldman Sachs Group started coverage on shares of Royalty Pharma in a research note on Tuesday, September 30th. They issued a “buy” rating and a $42.00 price target on the stock. Finally, Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $45.60.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.